Sponsors (42)
The bill clarifies and accelerates FDA rules for 'nonclinical' tests—improving regulatory clarity and predictability for researchers and health systems—at the cost of reduced public notice, potential short-term compliance costs, and some risk of interpretive gaps about which studies are covered.
Scientists and hospitals will face clearer, more consistent FDA rules because the bill defines 'nonclinical test' and clarifies regulatory language, reducing ambiguity and improving review predictability and compliance.
Researchers and patients with chronic conditions will get sooner-enforceable standards because the rule is implemented faster (within 1 year), giving industry and regulators clearer expectations sooner.
Patients and researchers lose the usual opportunity for public input because the bill makes the interim final rule immediately effective without the normal notice-and-comment period, reducing transparency and stakeholder feedback.
Patients and researchers could face regulatory gaps or disputes because narrowing statutory/regulatory language to 'nonclinical' may leave some studies ambiguous or uncovered, risking inconsistent oversight.
Hospitals, research teams, and sponsors may incur short-term compliance costs to update submissions, procedures, and systems because of the rapid implementation of the regulatory change.
Based on analysis of 2 sections of legislative text.
Requires FDA to publish an interim final rule within 1 year to replace generic/"animal" references with the defined term "nonclinical tests, data, studies, models, and research" and add a regulatory definition.
Official title: To require the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to publish a final rule relating to nonclinical testing methods.
Introduced April 10, 2025 by Buddy Carter · Last progress April 10, 2025
Directs the HHS Secretary, through the FDA Commissioner, to publish an interim final rule within one year to update FDA regulations so they use the term "nonclinical tests, data, studies, models, and research" (and the defined term "nonclinical test") instead of broader or generic references such as "animal." The interim final rule must amend specified CFR sections for consistency and is made effective immediately upon publication without the usual notice-and-comment good-cause finding. The bill also makes a technical redesignation of a subsection in 21 U.S.C. 355.